The Animal Drug Compounding Market To Witness Discrete Growth
In order to provide medical therapy suitable for individual animal needs, compounded drugs
are available, containing the desired active ingredients. For instance, currently, no FDA
approved drug is available in the market for the treatment of megacolon (constipation) in cats.
In 2000, Cisapride, the only safe and effective therapy for the treatment of chronic constipation
in cats was removed from the U.S. human market. Hence, compounding remains the only
choice for veterans to provide cisapride for animals in need of effective pro-kinetic drug
therapy. This is likely to create a conducive atmosphere for the growth of the animal drug
compounding market. In addition, drugs containing bromides were also removed from the U.S.
market in the 1970s; however, due to the safety and extended efficacy of bromides, the drug is
prescribed by compounding veterinarians for the treatment of idiopathic epilepsy in dogs.
The coronavirus pandemic is believed to have had a negative impact on the animal drug
compounding market. Due to disruptions in the supply chain, there has been significant
shortage in the supply of APIs. As coronavirus has become the main focus, all biotech
companies, pharmaceutical companies, and research institutes are working in collaboration to
deal with Covid-19. This is resulting in shifting focus and also other resources from making
other drugs for coronavirus vaccines.
Persistence Market Research predicts that the global animal drug compounding market will
exhibits an impressive 8% CAGR during the forecast period (2020-2030).
Get Sample Copy of this
Key Takeaways from Animal Drug Compounding Market Study
CNS agents are expected to dominate the global animal drug compounding market,
increasing at a CAGR of around 8%.
Companion animals are expected to hold the largest revenue share for animal drug
compounding during the forecast period.